Kodiak Sciences Inc.

NASDAQ: KOD · Real-Time Price · USD
3.98
0.04 (1.02%)
At close: Jun 04, 2025, 3:59 PM
4.10
2.85%
After-hours: Jun 04, 2025, 07:34 PM EDT

Company Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases.

Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD.

The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.

Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc.
Kodiak Sciences Inc. logo
Country United States
IPO Date Oct 4, 2018
Industry Biotechnology
Sector Healthcare
Employees 109
CEO Dr. Victor Perlroth M.D.

Contact Details

Address:
1200 Page Mill Road
Palo Alto, California
United States
Website https://kodiak.com

Stock Details

Ticker Symbol KOD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001468748
CUSIP Number 50015M109
ISIN Number US50015M1099
Employer ID 27-0476525
SIC Code 2836

Key Executives

Name Position
Dr. Victor Perlroth M.D. Co-Founder, Chairman, Chief Executive Officer & President
John A. Borgeson CPA, M.B.A. Executive Vice President, Chief Financial Officer & Secretary
Almas Qudrat M.Sc. Chief Quality Officer
Dr. Dolly S. Chang M.D., M.P.H., Ph.D. Chief Scientific Officer
Dr. Hong Liang Ph.D. Senior Vice President of Development
Dr. J. Pablo Velazquez-Martin M.D. Chief Medical Officer
Dr. Laurent Ducay Ph.D. Senior Vice President of Biologics Development & Manufacturing
Dr. Stephen Raillard Ph.D. Senior Vice President of Chemical Development & Manufacturing

Latest SEC Filings

Date Type Title
Jun 03, 2025 8-K Current Report
May 14, 2025 10-Q Quarterly Report
May 14, 2025 8-K Current Report
Apr 29, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 22, 2025 ARS Filing
Apr 22, 2025 DEFA14A Filing
Apr 22, 2025 DEF 14A Filing
Mar 27, 2025 S-8 Filing
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report